Clinicopathological and genomic analysis of SWI/SNF chromatin remodeling abnormalities with a focus on SMARCA4 in cancer of unknown primary.

ABSTRACT:

Purpose

The estimation of the primary site is crucial when considering chemotherapy regimens in cancer of unknown primary (CUP). The task is particularly challenging for poorly differentiated or undifferentiated carcinoma, or unknown histological tumors with unknown primary (U-CUP). Instead of site-specific chemotherapy, a biomarker-guided therapy using genomic testing is required to predict the efficacy of molecular-targeted agents and immune checkpoint inhibitors (ICI). We focused on inactivating the SWI/SNF complex, a chromatin regulatory complex. We investigated the clinical features of CUP with SWI/SNF chromatin remodeling abnormalities and examined whether SWI/SNF chromatin remodeling abnormalities are a predictive marker of ICI efficacy.

Methods

A multi-institutional

SUBMITTER: Tono Y 

PROVIDER: S-EPMC12390907 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature